RESUMEN
BACKGROUND: Although prior studies indicate a high prevalence of atrial fibrillation (AF) in patients with pulmonary embolism (PE), the exact prevalence and prognostic impact are unknown. METHODS: We aimed to investigate the prevalence, risk factors and prognostic impact of AF on risk stratification, in-hospital adverse outcomes and mortality in 528 consecutive PE patients enrolled in a single-centre registry between 09/2008 and 09/2017. RESULTS: Overall, 52 patients (9.8%) had known AF and 57 (10.8%) presented with AF on admission; of those, 34 (59.6%) were newly diagnosed with AF. Compared to patients with no AF, overt hyperthyroidism was associated with newly diagnosed AF (OR 7.89 [2.99-20.86]), whilst cardiovascular risk comorbidities were more frequently observed in patients with known AF. Patients with AF on admission had more comorbidities, presented more frequently with tachycardia and elevated cardiac biomarkers and were hence stratified to higher risk classes. However, AF on admission had no impact on in-hospital adverse outcome (8.3%) and in-hospital mortality (4.5%). In multivariate logistic regression analyses corrected for AF on admission, NT-proBNP and troponin elevation as well as higher risk classes in risk assessment models remained independent predictors of an in-hospital adverse outcome. CONCLUSION: Atrial fibrillation is a frequent finding in PE, affecting more than 10% of patients. However, AF was not associated with a higher risk of in-hospital adverse outcomes and did not affect the prognostic performance of risk assessment strategies. Thus, our data support the use of risk stratification tools for patients with acute PE irrespective of the heart rhythm on admission.
Asunto(s)
Fibrilación Atrial/epidemiología , Embolia Pulmonar/epidemiología , Medición de Riesgo , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Estudios de Cohortes , Comorbilidad , Femenino , Alemania/epidemiología , Mortalidad Hospitalaria , Humanos , Hipertiroidismo/epidemiología , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Péptido Natriurético Encefálico/sangre , Fragmentos de Péptidos/sangre , Pronóstico , Sistema de Registros , Troponina/sangreRESUMEN
Heart failure and atrial fibrillation are common and responsible for significant mortality of patients. Both share the same risk factors like hypertension, ischemic heart disease, diabetes, obesity, arteriosclerosis, and age. A variety of microscopic and macroscopic changes favor the genesis of atrial fibrillation in patients with preexisting heart failure, altered subcellular Ca2+ homeostasis leading to increased cellular automaticity as well as concomitant fibrosis that are induced by pressure/volume overload and altered neurohumoral states. Atrial fibrillation itself promotes clinical deterioration of patients with preexisting heart failure as atrial contraction significantly contributes to ventricular filling. In addition, atrial fibrillation induced tachycardia can even further compromise ventricular function by inducing tachycardiomyopathy. Even though evidence has been provided that atrial functions significantly and independently of confounding ventricular pathologies, correlate with mortality of heart failure patients, rate and rhythm controls have been shown to be of equal effectiveness in improving mortality. Yet, it also has been shown that cohorts of patients with heart failure benefit from a rhythm control concept regarding symptom control and hospitalization. To date, amiodarone is the most feasible approach to restore sinus rhythm, yet its use is limited by its extensive side-effect profile. In addition, other therapies like catheter-based pulmonary vein isolation are of increasing importance. A wide range of heart failure-specific therapies are available with mixed impact on new onset or perpetuation of atrial fibrillation. This review highlights pathophysiological concepts and possible therapeutic approaches to treat patients with heart failure at risk for or with atrial fibrillation.
Asunto(s)
Fibrilación Atrial , Terapia de Resincronización Cardíaca/métodos , Ablación por Catéter/métodos , Atrios Cardíacos/fisiopatología , Insuficiencia Cardíaca , Volumen Sistólico/fisiología , Anticoagulantes/uso terapéutico , Fibrilación Atrial/mortalidad , Fibrilación Atrial/fisiopatología , Fibrilación Atrial/terapia , Salud Global , Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Humanos , Pronóstico , Tasa de Supervivencia/tendenciasAsunto(s)
Anticoagulantes/uso terapéutico , Desfibriladores Implantables , Marcapaso Artificial , Pautas de la Práctica en Medicina/estadística & datos numéricos , Administración Oral , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Austria , Alemania , Hemorragia/inducido químicamente , Encuestas y Cuestionarios , Suiza , Tromboembolia/prevención & controlRESUMEN
INTRODUCTION: The extent of left atrial (LA) adverse remodeling as a cardiac disease marker has become increasingly important. In patients with atrial fibrillation (AF), atrial remodeling (AR) is accompanied by increased mortality. The relation between LA function and the extent of low-voltage areas (LVAs) has not yet been systematically investigated. METHODS: In patients with AF undergoing catheter-ablation, LA was studied using echocardiography and ultra-high-density mapping (Rhythmia®). Fibrosis (i.e. extent of LVAs) was estimated by quantifying areas with bipolar electrogram amplitudes of ≤0.5, ≤0.4, ≤0.3, ≤0.2 or ≤0.1â¯mV. RESULTS: A total of 22 patients with a mean LVEF of 53⯱â¯2% was studied. Mean LA volume index (LAVI) was significantly increased at 39⯱â¯3â¯ml/m2 indicating AR. Size of LVAs was 57⯱â¯7â¯cm2 representing 47⯱â¯5% of the total LA area (low-voltage set to ≤0.5â¯mV). With low-voltage set to ≤0.4, ≤0.3, ≤0.2 and ≤0.1, total area decreased to 34⯱â¯6, 28⯱â¯6, 22⯱â¯5 and 12⯱â¯3â¯cm2. LAVI positively correlated with the extent of LVAs at all cut-offs. Mean LA emptying fraction was 42⯱â¯3% and showed a negative correlation with LVAs with low-voltage set to ≤0.4â¯mV. Moreover, mean LA strain was 13⯱â¯2% and correlated with LVAs with low-voltage at all cut-offs further supporting the notion that the extent of LVAs impacts LA function. Notably, with low-voltage set to ≤0.2, ≤0.3 and ≤0.4â¯mV impaired LA strain was detected with an accuracy of >76% (pâ¯<â¯0.05). CONCLUSION: Structural (i.e. LAVI) and functional (i.e. LA emptying fraction and LA strain) parameters of the LA correlate with the extent of LVAs.